Screener
Protagonist Therapeutics PTGX Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Employee wages and benefits - discovery (2) | (2,668) | (2,188) | (5,816) | (4,515) |
| Employee wages and benefits - development (2) | (4,949) | (4,658) | (10,901) | (10,142) |
| Employee wages and benefits - general and administrative | (4,357) | (3,483) | (9,080) | (7,315) |
| Stock-based compensation expense | (14,037) | (10,912) | (28,556) | (24,714) |
| Other segment items (3) | (81) | 36 | (28) | 118 |
| Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
| Income tax expense | (2,265) | (172) | (763) | (172) |
| Consolidated net income (loss) | $162,849 | $(34,771) | $166,632 | $(46,426) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's business segments — allocated share based compensation expense?
- Protagonist Therapeutics (PTGX) reported business segments — allocated share based compensation expense of $14.04M in Q2 2026.
- How has Protagonist Therapeutics's business segments — allocated share based compensation expense changed year-over-year?
- Protagonist Therapeutics's business segments — allocated share based compensation expense increased by 28.6% year-over-year, from $10.91M to $14.04M.
- What is the long-term trend for Protagonist Therapeutics's business segments — allocated share based compensation expense?
- Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — allocated share based compensation expense has grown at a 23.8% compound annual growth rate (CAGR), from $24.2M to $45.97M.
- What does business segments — allocated share based compensation expense mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees and directors across the organization. It is a critical component of total compensation that aligns the interests of the workforce with long-term shareholder value. Investors monitor this to understand the dilution impact and the total cost of talent acquisition and retention.
Ask your AI about Protagonist Therapeutics's business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude